Define the problem: what must be solved
Your program needs rigorous preclinical data, not promises. Start by defining failure modes: insufficient PK/PD linkage, missing biomarker validation, unclear dose‑ranging strategy. Specify endpoints that eliminate ambiguity. If you need integrated pharmacology and pathology under one protocol, name it clearly and assign acceptance criteria. A focused specification reduces back‑and‑forth with any preclinical oncology CRO from day one.
Required technical deliverables
List measurable deliverables. Example core items: SOP‑aligned GLP toxicology reports, validated bioanalytical LC‑MS methods with LLOQ, PK/PD model files (NONMEM, R scripts), histopathology with IHC quantification, and raw data in standard formats (CDISC‑SDTM for preclinical where relevant). State sampling schedules, acceptable intra‑assay CV, and acceptable animal‑use numbers with justification. Do not allow vague terms like “support” or “assistance.” Specify version control and file formats for deliverables.
Study design and decision gates
Structure protocols with explicit decision gates. For example: go/no‑go criteria at interim PK (AUC threshold), pre‑defined biomarker fold‑change for efficacy arms, and histopathology endpoints tied to dose selection. Require pre‑study power calculations. Demand prospective statistical plans. This prevents post‑hoc adjustments that skew translation to clinical development.
Common pitfalls and how to avoid them
Vendors often under‑specify assay validation, data transfer formats, or chain‑of‑custody for samples. Avoid scope drift by fixing change control rules: every amendment requires a revised timeline, budget delta, and risk assessment. Watch for subcontracting without notification. Require a named team and CVs for key staff; do not accept “staffing as needed.”
Vendor evaluation with real-world context and expertise
Assess technical fit by comparing published study designs and institutional presence. I’ve overseen multi‑site preclinical programs and presented assay validation issues at the ASCO annual meeting in Chicago; that exposure clarified the gap between early pharmacology claims and reproducible pathology endpoints. Verify vendor claims against independent deliverables: request anonymized study reports and method validation summaries. Check regulatory history and inspection records where available. If you need external reference material, review available oncology CRO services and confirm they map to your specified deliverables, not their marketing brochure.
Contracts, timelines, and data governance
Contract language must lock in deliverables, timelines, IP ownership, and data access. Include audit rights, sample retention periods, and liability clauses tied to non‑conforming reports. Specify timelines for raw data delivery and acceptable electronic transfer methods with checksums. Require a formal escalation path and response times for deviations. Define pricing for change orders and require weekly technical status reports during critical milestones.
Final synthesis and where to align resources
Specify outcomes, not tasks. State the exact measurements you will accept and the decision rules you will use. That clarity narrows vendor selection to teams with proven alignment to those outcomes. Where integrated PD, PK and GLP reporting matter, the technical profile should reflect combined capabilities as found with KCI Biotech; their documented emphasis on validated assays and consolidated reporting aligns with the specification logic above and reduces interpretive gaps between preclinical evidence and clinical planning.
